

Intraoperative calculus or hemorrhage in transurethral seminal vesiculoscopy as a risk factor for recurrent hemospermia

Cheng-En Mei^{1, 2}, Ju-Chuan Hu², Jian-Ri Li², Kun-Yuan Chiu², Shian-Shiang Wang², Chuan-Shu Chen²

*

¹Division of Traumatology, Department of Emergency Medicine, Taichung Veterans General Hospital, Taichung, Taiwan

²Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan

* Corresponding author

E-mail: r2060d@gmail.com (CSC)

12 Abstract

13 We summarized our experience regarding Transurethral Seminal Vesiculoscopy (TUSV) and
 14 analyzed both recurrence status and risk factors for recurrence. From January 2010 to December
 15 2020, 48 patients with intractable hemospermia received successful TUSV at Taichung Invalids
 16 General Hospital. For the intraoperative findings, the five-year Disease-free Survival rates (DFS)
 17 were 74.1% in the no calculus group compared to 37.1% in the calculus group with a significant
 18 difference (log-rank $p = 0.015$), 75.0% in the no hemorrhage or no blood clot group compared to
 19 43.2% in the hemorrhage or blood clot group with significant difference (log-rank $p = 0.032$).
 20 Univariate analysis showed intraoperative calculus ($p = 0.040$; HR: 2.94, 95% CI: 1.05–8.21) to be
 21 significantly associated with recurrence ($p < 0.05$). Patients with intractable hemospermia who
 22 were diagnosed with stones or blood clots found during TUSV experienced a higher rate of
 23 hemospermia recurrence.

24 Introduction

25 Hemospermia, hematospermia, or haematospermia is defined as blood appearance in the
 26 semen. [1] The symptom usually resolves spontaneously in most cases. The mechanisms
 27 surrounding the occurrence of hemospermia can be inflammation, infection, lithiasis, cyst
 28 formation, obstruction, tumor, vascular related, trauma, iatrogenic related and systemic origin.
 29 Recommended imaging studies include Transrectal Ultrasound (TRUS), Computed Tomography
 30 (CT), and Magnetic Resonance Imaging (MRI). [2] TRUS is less expensive and less diagnostic than
 31 the other tests, but is more commonly used as a diagnostic tool. [3, 4]

32 Through advancements in endoscopy technology, in vivo Transurethral Seminal Vesiculoscopy
 33 (TUSV) was first introduced in 2002. [5] Subsequently, TUSV has been used as a diagnostic and
 34 treatment procedure for recurrent hemospermia, persistent hemospermia and intractable
 35 hemospermia, with symptoms persisting over 3 months regardless of medical treatment. [6-11]
 36 TUSV also has a higher diagnostic rate than TRUS. [3]

37 The recurrence rate after TUSV treatment has been mentioned to be in a range from 3.4% to
 38 11.76%. [6-11] To the best of our knowledge, there are currently no studies investigating
 39 recurrence after TUSV. In this study, we sorted through 48 successful cases and analyzed their
 40 recurrence status and risk factors for recurrence.

41 **Materials and Methods**

42 **Patients**

43 This study enrolled patients who had intractable hemospermia and received successful TUSV
44 treatment during the period from January 2010 to December 2020 in Taichung Veterans General
45 Hospital, Taiwan, Republic of China. The diagnosis of hemospermia relied on photos of semen
46 which patients took after sexual activity. The enrolled patients took serum Prostate-specific
47 Antigen (PSA), coagulation tests and TRUS.

48 For the treatment of hemospermia, an empiric antibiotic ciprofloxacin, 400 mg every 12
49 hours per os (PO), was administered for at least 2 weeks. For patients with intractable
50 hemospermia who were willing to undergo surgery to relieve symptoms, we provided TUSV.

51 The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki
52 and was granted by the ethics committee of Taichung Veterans General Hospital, Taiwan, Republic
53 of China. The institutional review board number was CE22060A.

54 **Surgical techniques**

55 Each patient received either general anesthesia or spinal anesthesia and was placed in the
56 lithotomy position. A semi-rigid ureteroscope (6/7.5-Fr; Olympus, Tokyo, Japan) was inserted into
57 the urethra and introduced to the verumontanum. The bilateral seminal vesicles were then
58 entered through the ejaculation duct or fenestrated from the utricle. Intraoperative
59 manifestations, such as Calculus, hemorrhage, mucosal lesion, were recorded. Seminal vesicle fluid
60 would then be collected for a culture exam. Calculus removal or a biopsy would be performed

61 depending on intraoperative manifestations. After the procedure, 10ml normal saline with 80mg
62 gentamycin irrigation into the seminal vesicle would then be done. [9]

63 **Statistical analysis**

64 Numeric variables are expressed as medians (interquartile ranges) and subsequently
65 compared using the Chi-square test, with significance set at $p < 0.05$. Continuous variables are
66 presented as medians (ranges) and compared using the Mann-Whitney U test, with significance
67 also set at $p < 0.05$. Rates of Disease-free Survival (DFS) up to January 2022 were calculated using
68 the Kaplan-Meier life table method and compared across groups using the log-rank test.
69 Differences with p values < 0.05 were regarded as statistically significant. Univariate and
70 multivariate analysis utilizing Cox proportional hazard ratios were derived for the outcomes of
71 interest. All p values < 0.05 were considered significant in univariate analysis and thus included in
72 multivariate analyses.

73 **Result**

74 Forty-eight (48) patients diagnosed with intractable hemospermia who underwent successful
75 TUSV were studied. All patients achieved remission. Sixteen (16) patients (33.3%) underwent
76 recurrence up until January 2022. The characteristics between recurrence and non- recurrence are
77 shown in Table 1. In TURS findings, 22 non-recurrent patients (68.8%) experienced overall calculus,
78 while 13 recurrent patients (86.7%) had overall calculus. Eight non-recurrent patients (25%) had
79 Seminal Vesicle (SV) or ejaculation duct calculus, while 2 recurrent patients (13.3%) had SV or
80 ejaculation duct calculus. The median time of follow-up was 39.4 months in the non- recurrent
81 group and 49.8 months in the recurrent group. Complications such as epididymitis occurred in only
82 2 cases in the non-recurrent group. The median follow-up period was 40.1 months (range,
83 0.95–134.5 months).

Table 1. Characteristics of patients between recurrence and non-recurrence.

Total (n=48)	Non-recurrence (n=32)	Recurrence (n=16)	p value
Age	54.5 (48.3-63.8)	53.5 (38.3-58.8)	0.330
Duration (months)	12.0 (4.0-23.3)	13.0 (6.0-24.0)	0.676
Diabetes mellitus	2 (6.3%)	1 (6.3%)	1.000
Hypertension	6 (18.8%)	4 (25.0%)	0.712
Previous urinary tract infection	2 (6.3%)	1 (6.3%)	1.000
Urolithiasis history	5 (15.6%)	1 (6.3%)	0.648
Erectile dysfunction	4 (12.5%)	1 (6.3%)	0.652
Sexually transmitted disease	1 (3.1%)	0 (0.0%)	1.000
Anti-platelet agent	2 (6.3%)	3 (20.0%)	0.309
PSA	1.1 (0.6-1.4)	1.0 (0.7-1.7)	0.803
Digital rectal examination			
Elastic consistency	32 (100%)	16 (100%)	--
Hard consistency	0 (0%)	0 (0%)	--
TRUS findings			
Overall calcification	22 (68.8%)	13 (86.7%)	0.288
Prostate calculus	19 (59.4%)	13 (86.7%)	0.094
SV or ejaculation duct calculus	8 (25.0%)	2 (13.3%)	0.465
Post operative complication			
Epididymitis	2 (6.3%)	0 (0.0%)	0.546
Perineal pain	0 (0.0%)	0 (0.0%)	--
Follow-up period (months)	39.4 (1.6-66.1)	49.8 (20.9-96.7)	0.120
Time to remission (weeks)	4.0 (3.0-4.0)	4.0 (4.0-7.75)	0.097

Chi-square test or Mann-Whitney U test, Median (IQR). * $p < 0.05$, ** $p < 0.01$

Numeric variables expressed as medians (interquartile ranges)

Seminal vesicle (SV)

85 Intraoperative findings

86 Intraoperative findings of TUSV between the recurrence and non-recurrence groups are
87 shown in Table 2. Overall calculus was found in the utricle or SV in 10 non-recurrent patients
88 (31.3%) and 9 recurrent patients (56.3%). Hemorrhage was found in the utricle or SV in 11
89 non-recurrent patients (34.4%) and 10 recurrent patients (62.5%).

Table 2. Intraoperative findings of TUSV between recurrence and non-recurrence.

Total (n=48)	Non-recurrence (n=32)	Recurrence (n=16)	p value
Intraoperative findings			
Overall calculus	10 (31.3%)	9 (56.3%)	0.175
Utricle	10 (31.3%)	7 (43.8%)	0.594
Left SV	3 (10.0%)	4 (26.7%)	0.199
Right SV	2 (6.9%)	1 (6.3%)	1.000
Hemorrhage or blood clot	11 (34.4%)	10 (62.5%)	0.123
Utricle	2 (6.3%)	0 (0.0%)	0.546
Left SV	6 (20.7%)	7 (46.7%)	0.092
Right SV	4 (14.3%)	5 (31.3%)	0.250

Chi-square test. * $p < 0.05$, ** $p < 0.01$

Seminal vesicle (SV)

90 Disease free survival

91 Regarding the TRUS findings, five-year Disease-free Survival (DFS) rates were 75.0% in the no
92 calculus group compared to 59.0% in the overall calculus group, with the Kaplan–Meier survival
93 curves represented in Fig 1 (log-rank $p = 0.273$). The five-year DFS rates were 54.5% in the no SV or
94 ejaculation duct calculus group compared to 100.0% in the SV or ejaculation duct calculus group,
95 with the Kaplan–Meier survival curves represented in Fig 2 (log-rank $p = 0.227$). In this study, the
96 five-year DFS rates taken from the TRUS findings were insignificantly different.

97 **Fig 1. Kaplan–Meier curves of the disease-free survival rates by TRUS findings of overall**

98 **calcification.** No calcification compared to overall calcification

99 **Fig 2. Kaplan–Meier curves of the disease-free survival rates by TRUS findings of SV or**

100 **ejaculation duct stone.** No Seminal vesicle (SV) or ejaculation duct calculus compared to SV or

101 ejaculation duct calculus.

102 For the intraoperative findings, the five-year DFS rates were 74.1% in the no calculus group

103 compared to 37.1% in the calculus group, with the Kaplan–Meier survival curves represented in Fig

104 3 (log-rank $p = 0.015$). The five-year DFS rates were 75.0% in the no hemorrhage or blood clot

105 group compared to 43.2% in the hemorrhage or blood clot group, with the Kaplan–Meier survival

106 curves represented in Fig 4 (log-rank $p = 0.032$). The five-year DFS rates were 73.7% in the

107 negative intraoperative finding group compared to 47.7% in the positive intraoperative finding

108 group, with the Kaplan–Meier survival curves represented in Fig 5 (log-rank $p = 0.093$). In this study,

109 the five-year DFS rates were significant higher in the intraoperative no calculus group when

110 compared to the calculus group, and in the no hemorrhage or blood clot group when compared to

111 the hemorrhage or blood clot group. The five-year DFS rate was insignificant but trending upward

112 in intraoperative negative findings when compared to positive findings.

113 **Fig3. Kaplan–Meier curves of the disease-free survival rates by intraoperative findings of**

114 **calculus.** No calculus compared to overall calculus.

115 **Fig4. Kaplan–Meier curves of the disease-free survival rates by intraoperative findings of**

116 **hemorrhage or blood clot.** No hemorrhage or blood clot compared to hemorrhage or blood clot.

117 **Fig5. Kaplan–Meier curves of the disease-free survival rates by intraoperative findings.** Negative
118 intraoperative finding compared to positive intraoperative finding.

119 Univariate analysis showed intraoperative calculus ($p = 0.040$; HR: 2.94, 95% CI: 1.05–8.21) to
120 be significantly associated with recurrence, and intraoperative hemorrhage or blood clot ($p =$
121 0.068; HR: 2.63, 95% CI: 0.93–7.43) to be insignificant but trending upward with recurrence.

122 Multivariate Cox proportional hazard analysis showed intraoperative calculus ($p = 0.051$; HR: 2.80,
123 95% CI: 1.00–7.90) to be insignificant but trending upward with recurrence.

124 Discussion

125 Effectiveness of preoperative imaging

126 TRUS has been mentioned in other studies as having a lower diagnostic yield for hemospermia.
127 [3] In this study, preoperative TRUS provided a low SV or ejaculatory duct stone detection. TUSV
128 provides better diagnostic rates than a TRUS exam alone. This result is consistent with previous
129 research findings. In this study, TRUS results showed no significant difference in DFS. TRUS
130 findings also failed to provide an association with recurrence prediction. Although TRUS is
131 relatively less invasive and carries less cost, the diagnostic significance and benefit of TRUS in
132 patients with persistent hemospermia requires additional follow-up studies.

133 Recurrence and hypothesis of hemospermia

134 The recurrence rate after TUSV treatment is mentioned as being in the range of 3.4% to
135 11.76%. [6-11] Amongst the 48 patients in this study, 16 had recurrent hemospermia, with the
136 recurrence rate being 33.33%, which was higher than other studies. However, the median
137 follow-up time in our study was 40.1 months, while the follow-up time in other studies was 5-24
138 months. [6-11] Compared with the previous study performed in our hospital, the follow-up time
139 was 12 months, with 4 of 34 patients experiencing recurrence at a rate of 11.76%. [9] Our patients
140 were more regionalized so follow-up at the same hospital was easier. The high recurrence rate
141 may be related to the long follow-up time.

142 In our study, recurrence-free survival from intraoperative detected stones, hemorrhages, or
143 blood clot was significantly lower when compared with the undetected group. The current
144 hypothesis is that the occurrence of hemospermia, calculus, strictures and inflammation is a
145 vicious cycle. [3, 12] According to that hypothesis, TUSV could interrupt the vicious cycle in
146 addition to providing a diagnosis. For patients with negative intraoperative findings, we believe
147 that TUSV can block the vicious cycle of stricture and inflammation, thus resulting in symptom
148 relief with low recurrence rates. Inflammation may be worse in patients experiencing stones,
149 hemorrhage, or blood clots as detected by TUSV. Fortunately, TUSV can still stop the vicious
150 cycle and relieve symptoms. Because the inflammation is more severe, the possibility of
151 hemospermia recurrence will also increase.

152 **Success rate**

153 The success rate of TUSV treatment, as mentioned in the relevant literature, ranges from
154 90.9% to 96.53%.[8, 9, 11] In this study, 51 patients underwent TUSV, while 6 of them received
155 second TUSV due to recurrent hemospermia. Among the total 57 TUSV treatments, 54 of which
156 were successfully performed. Such a success rate of 94.7% is comparable with the studies
157 reported in the relevant literature. The 3 patients whose TUSV failed all received MRI exams. It
158 turned out that one of them had a seminal vesicle cyst, while the other 2 patients had small
159 prostate cysts. These structural abnormalities may affect the orientation of the ejaculatory ducts
160 or the location of the seminal vesicles, thereby affecting the success rate of TUSV.

161 **Safety considerations**

162 Perineal pain, retrograde ejaculation, epididymitis, prolonged hematuria, rectal injury and
163 urinary incontinence are known complications of TUSV. [9, 14] Only 2 patients in this study had
164 postoperative complication of epididymitis. After antibiotic treatment, the infection in these 2
165 patients was eventually controlled and resolved. Some studies have raised concerns that
166 disruption of normal structures by TUSV could lead to infertility. [14] In recent studies, endoscopic
167 treatments including both TUSV and Transurethral Ejaculation Duct resection (TURED) have shown
168 positive results in the treatment of infertility. [10, 15-18] Real-time TRUS-guided TUSV has also
169 been reported as being a safe procedure that helps avoid rectal injury. [19] Therefore, this study
170 provides strong evidence for the safety of TUSV.

171 **Limitations and future prospects**

172 The present study is retrospective and with a rather small sample size. Further prospective
173 studies with more patients involved would provide more convincing reference and therefore
174 stronger evidence. Besides the aforementioned limitations, the condition of patients with
175 hemospermia usually improves spontaneously without any aggressive treatment. Furuya et al.
176 reported that the spontaneously resolved rate of hemospermia is as high as 88.9%. [19] It is
177 possible that at the time of analysis, this natural process, i.e. hemospermia being relieved
178 spontaneously, had, to a certain extent, contributed to the excellent remission rate after TUSV as
179 well as complicated the assumed cause-and-effect relationship between TUSV and the remission
180 of hemospermia.

181 **Conclusion**

182 As analyzed and concluded in this present study, intraoperative findings can help assess the
183 risk of recurrent hemospermia. Specifically speaking, stones or blood clots found during TUSV for
184 patients with intractable hemospermia contribute to a higher rate of recurrent hemospermia.

185 **Acknowledgments**

186 We would like to thank the editors of PLOS ONE and the reviewers for their thoughtful comments
187 that helped us strengthen this article.

References

1. Kumar, P., S. Kapoor, and V. Nargund, *Haemospermia - a systematic review*. Ann R Coll Surg Engl, 2006. 88(4): p. 339-42.
2. Suh, Y., et al., *Etiologic classification, evaluation, and management of hematospermia*. Transl Androl Urol, 2017. 6(5): p. 959-972.
3. Xing, C., et al., *Prospective trial comparing transrectal ultrasonography and transurethral seminal vesiculoscopy for persistent hematospermia*. Int J Urol, 2012. 19(5): p. 437-42.
4. Han, H., et al., *Magnetic resonance imaging compared to ultrasound as the preferred method for diagnosing intractable haemospermia*. Andrologia, 2021. 53(6): p. e14054.
5. Yang, S.C., et al., *Transutricular seminal vesiculoscopy*. J Endourol, 2002. 16(6): p. 343-5.
6. Han, W.K., et al., *Transutricular seminal vesiculoscopy in hematospermia: technical considerations and outcomes*. Urology, 2009. 73(6): p. 1377-82.
7. Kang, P.M., et al., *Transutricular seminal vesiculoscopy in the management of symptomatic midline cyst of the prostate*. World J Urol, 2016. 34(7): p. 985-92.
8. Chen, R., et al., *Transurethral seminal vesiculoscopy for recurrent hemospermia: experience from 419 cases*. Asian J Androl, 2018. 20(5): p. 438-441.
9. Hu, J.C. and C.S. Chen, *Transurethral seminal vesiculoscopy acts as a therapeutic investigation for intractable hemospermia: Step-by-step illustrations and single-surgeon experience*. Int J Urol, 2018. 25(6): p. 589-595.
10. Liao, L.G., et al., *Etiology of 305 cases of refractory hematospermia and therapeutic options*

- 208 *by emerging endoscopic technology*. Sci Rep, 2019. 9(1): p. 5018.
- 209 11. Chen, W.K., et al., *Transurethral seminal vesiculoscopy for intractable hematospermia:*
210 *experience from 144 patients*. BMC Urol, 2021. 21(1): p. 48.
- 211 12. Ren, Z.J., et al., *Transurethral resection of ejaculatory duct combined with seminal*
212 *vesiculoscopy for management of persistent or recurrent hemospermia in men with*
213 *ejaculatory duct obstruction*. BMC Urol, 2020. 20(1): p. 34.
- 214 13. Furuya, S., N. Masumori, and A. Takayanagi, *Natural history of hematospermia in 189*
215 *Japanese men*. Int J Urol, 2016. 23(11): p. 934-940.
- 216 14. Pang, K., B.Z. Dong, and C.H. Han, *Commentary on "Transurethral seminal vesiculoscopy for*
217 *recurrent hemospermia: experience from 419 cases"*. Asian J Androl, 2020. 22(2): p.
218 227-228.
- 219 15. Dong, Q., et al., *[Minimally invasive surgery for ejaculatory duct obstruction in infertile*
220 *men]*. Zhonghua Nan Ke Xue, 2016. 22(4): p. 291-3.
- 221 16. Tang, S.X., H.L. Zhou, and Y.L. Ding, *[Effectiveness of transurethral seminal vesiculoscopy in*
222 *the treatment of persistent hematospermia, and oligoasthenozoospermia and azoospermia*
223 *from ejaculatory duct obstruction]*. Zhonghua Yi Xue Za Zhi, 2016. 96(36): p. 2872-2875.
- 224 17. Lira, F.T.N., et al., *Management of Ejaculatory Duct Obstruction by Seminal Vesiculoscopy:*
225 *Case Report and Literature Review*. JBRA Assist Reprod, 2020. 24(3): p. 382-386.
- 226 18. Wang, H.B., et al., *[Transurethral seminal vesiculoscopy in treatment of*
227 *oligoasthenozoospermia secondary incomplete ejaculatory duct obstruction: A report of 8*

228 cases]. Beijing Da Xue Xue Bao Yi Xue Ban, 2020. 52(4): p. 642-645.

229 19. Wang, X.S., et al., *Real-time transrectal ultrasound-guided seminal vesiculoscopy for the*
 230 *treatment of patients with persistent hematospermia: A single-center, prospective,*
 231 *observational study.* Asian J Androl, 2020. 22(5): p. 507-512.

232

233 **Supporting information**

234 **S1 File. Raw data. File containing data of TUSV follow-up, TRUS findings, Intraoperative findings**
 235 **and recurrence**




Fig 1. Kaplan-Meier curves of the disease-free survival rates by T




Fig 2. Kaplan-Meier curves of the disease-free survival rates by T




Fig3. Kaplan-Meier curves of the disease-free survival rates by in




Fig4. Kaplan-Meier curves of the disease-free survival rates by in




Fig5. Kaplan-Meier curves of the disease-free survival rates by intraoperative finding